Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...

No longer confined to cancer centers, skin complications of cancer therapies are now commonly encountered at the community level and require the care of a dermatologist.

Neuropathy, skin rash, and hyperglycemia are linked to improved PFS in patients treated with enfortumab vedotin for metastatic urothelial carcinoma. Patients experiencing these side effects had longer ...

A research team from the UCLA Health Jonsson Comprehensive Cancer Center, the University of Texas MD Anderson Cancer Center, and collaborators have demonstrated that a novel topical BRAF inhibitor gel ...

Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life Acne-like skin rash is a common side effect from colorectal ...

Nearly every medication comes with side effects, and in cancer therapies, they can be severe. Clinicians must often weigh the benefits of treatment against potential adverse effects. At the 29th ...

LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...

Colon cancer, also called colorectal cancer, mainly affects the large intestine and rectum. It is among the most common cancers in the UK and globally, impacting thousands of lives each year. While ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...